USC study maps brain network changes linked to bipolar disorder severity and treatment
Peer-Reviewed Publication
Updates every hour. Last Updated: 11-Jun-2026 11:15 ET (11-Jun-2026 15:15 GMT/UTC)
New historical research has found that early stagecoach passengers were as concerned with motion sickness as they were with the risk of being robbed by highwaymen.
New research found that extreme heat is already influencing how people with cancer manage daily life, access care, and make treatment-related decisions. The study highlights the need to integrate environmental risk into cancer care planning, from clinical conversations and appointment planning to caregiver guidance and community support.
"Menopause brain" is real, and now there is scientific proof. New findings by neuroscience researchers at the Larner College of Medicine reveal how menopause affects brain function. Their findings suggest that menopause represents an important neurological transition that may influence cognitive experiences in the present and long-term brain aging. This study is among the first to demonstrate these changes using resting-state brain activity.
A common concern for accepting immigrants is their effect on the host country’s welfare system. In a redistributive welfare system, where immigrants participate in the healthcare system, natives are inclined towards accepting high-income immigrants. A new study explores this question through a novel survey experiment, establishing a causal link between the perception of immigrants’ participation in the healthcare system and preferences towards different types of immigrants.
Virtually all people with Down syndrome develop brain changes associated with Alzheimer’s disease by age 40, and approximately 95% will go on to develop dementia due to Alzheimer’s, now the leading cause of death among adults with Down syndrome. John and Tami Marick understand firsthand the devastating effects Alzheimer’s disease has on loved ones, and the risk it poses to those with Down syndrome. The Maricks launched the JTMF Foundation in 2021 to fulfill a mission to improve the lives of people in need, including empowering individuals with intellectual and developmental disabilities. The Maricks fortuitously met Michael Rafii, MD, PhD, medical director of the USC Epstein Family Alzheimer’s Therapeutic Research Institute (ATRI) and principal investigator of the Alzheimer’s Clinical Trials Consortium – Down syndrome (ACTC-DS). As a result, the JTMF Foundation has expanded its footprint with a game-changing $3.3 million gift to USC to fund three main initiatives: funding five gold-standard Vanguard Clinical Trial Sites in the United States for four years; supporting the launch of a clinical trial site at Oregon Health & Science University (OSHU) to bring access to advances in Alzheimer’s treatments to individuals with Down syndrome in the area; and funding the first-of-its-kind Research Ambassador Program employing individuals with Down syndrome at clinical trial sites.
Nanjing University researchers report a breakthrough siRNA delivery strategy that transforms the liver into a "biopharmaceutical factory" for targeted cancer therapy. The team developed an In Vivo Self-Assembled (IVSA) system that uses intravenously injected plasmid DNA to program hepatocytes to produce and package EGFR-targeting siRNA into GE11-tagged small extracellular vesicles. These "biomissiles" selectively deliver therapeutic siRNA to EGFR-positive tumors, overcoming the long-standing siRNA delivery challenge without complex in vitro encapsulation. The system demonstrated potent efficacy across EGFR-mutant lung cancer, gastric cancer, and breast cancer models, outperforming traditional targeted drugs while showing minimal off-target toxicity. This plug-and-play platform represents a paradigm shift from conventional drug manufacturing to in vivo biopharmaceutical production, offering a modular, cost-effective approach for personalized cancer gene therapy.